证券代码：688319 证券简称：欧林生物 公告编号：2025-039 成都欧林生物科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 一、股票交易异常波动的具体情况 公司股票于 2025 年 8 月 18 日、2025 年 8 月 19 日、2025 年 8 月 20 日连续三 个交易日收盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》 《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交 易异常波动的情形。 成都欧林生物科技股份有限公司股票于 2025 年 8 月 18 日、2025 年 8 月 19 日、2025 年 8 月 20 日连续三个交易日收盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异 常交易实时监控细则》的有关规定，属于股票交易异常波动的情形。 经公司自查，公司目前日常经营情况正常，未发生重大变化。经公司向 控股股东、实际控制人书面询证，截至本公告披露日，公司不存在应披 露而 ...

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. is adjusting its fundraising plan to raise a total of 125.29 million yuan for a vaccine research and production base technology transformation project, down from 175.29 million yuan [1][2][4] Group 1: Trading Information - On August 19, 2025, Olin Biological's stock closed at 31.21 yuan, up 12.71%, with a turnover rate of 6.8% and a trading volume of 275,600 shares, amounting to a total transaction value of 831 million yuan [1] - The fund flow on August 19 showed a net outflow of 5.9961 million yuan from main funds, a net inflow of 24.9017 million yuan from speculative funds, and a net outflow of 18.9056 million yuan from retail investors [1][3] Group 2: Fundraising Plan - The company plans to issue A-shares through a simplified procedure, with the total investment for the vaccine research and production base technology transformation project set at 290 million yuan, of which 125.29 million yuan will be raised through this issuance [3][4] - The number of shares to be issued has been adjusted from 12,785,769 shares to 9,138,795 shares, with the issue price set at 13.71 yuan per share [2][5] Group 3: Project Impact - The project aims to enhance the automation level and production efficiency of the production line, ensuring product quality and safety, and meeting market demand to strengthen the company's competitive advantage [3][4] - The company has committed to measures to mitigate the dilution of immediate returns from this issuance, including increasing R&D investment and accelerating the construction of the funded projects [5]

欧林生物8月19日大宗交易平台共发生2笔成交，合计成交量47.79万股，成交金额1059.03万元。成交价 格均为22.16元，相对今日收盘价折价29.00%。 证券时报·数据宝统计显示，欧林生物今日收盘价为31.21元，上涨12.71%，日换手率为6.80%，成交额 为8.31亿元，全天主力资金净流出682.48万元，近5日该股累计上涨52.24%，近5日资金合计净流入 9091.51万元。 两融数据显示，该股最新融资余额为2.59亿元，近5日增加4039.54万元，增幅为18.47%。（数据宝） 8月19日欧林生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 33.60 | 744.58 | 22.16 | -29.00 | 华泰证券股份有限公司成 | 华泰证券股份有限公司成 | | | | | | 都人民南路证券营业部 | 都人民南路证券营业部 | | 14.19 ...

8月19日，欧林生物大宗交易成交47.79万股，成交额1059.03万元，占当日总成交额的1.26%，成交价22.16元，较市场收盘价31.21元折价29%。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) | 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-19 | 欧林生物 | 688319 | 22.16 | 744.58 | 33.6 | 华泰证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司成都人民南路 | 公司成都人民南路 | | | | | | | | 证券营业部 | 证券营业部 | | 2025-08-19 | 欧林生物 | 688319 | 22.16 | 314.45 | 14.19 | 华泰证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司成都人民南路 | 公司成都人民南路 | | | | | | | | 证券营业部 | 证券营业部 | ...

Market Overview - The biopharmaceutical sector increased by 0.27% on August 19, with Olin Bio leading the gains [1] - The Shanghai Composite Index closed at 3727.29, down 0.02%, while the Shenzhen Component Index closed at 11821.63, down 0.12% [1] Top Performers - Olin Bio (688319) closed at 31.21, up 12.71% with a trading volume of 275,600 shares and a transaction value of 831 million [1] - Nossland (430047) closed at 28.44, up 11.53% with a trading volume of 211,700 shares and a transaction value of 622 million [1] - Ganli Pharmaceutical (603087) closed at 68.03, up 6.95% with a trading volume of 406,100 shares and a transaction value of 2.793 billion [1] Underperformers - Junshi Biosciences (688180) closed at 45.32, down 3.70% with a trading volume of 210,400 shares and a transaction value of 977 million [2] - ZhiXiangQuanTai (688443) closed at 33.05, down 3.42% with a trading volume of 77,200 shares and a transaction value of 260 million [2] - SanShengGuoJian (688336) closed at 54.10, down 2.50% with a trading volume of 85,900 shares and a transaction value of 477 million [2] Capital Flow - The biopharmaceutical sector saw a net inflow of 250 million from institutional investors, while retail investors experienced a net outflow of 379 million [2][3] - Major stocks like Shenzhou Cell (688520) had a net inflow of 1.39 billion from institutional investors, but a net outflow of 1.08 billion from retail investors [3]

Group 1 - The company held its second board meeting of the seventh session on August 18, 2025, with all nine directors present, and the meeting was deemed legally valid [2][3]. - The board approved a proposal to reduce the total amount of funds raised through a simplified procedure for issuing shares to specific targets from 175.29 million yuan to 125.29 million yuan [3][7]. - The number of shares to be issued was adjusted from 12,785,769 shares to 9,138,795 shares, which does not exceed 30% of the company's total share capital before the issuance [4][6]. Group 2 - The adjusted total amount of funds to be raised is 125.29 million yuan, which is still within the limit of 300 million yuan and does not exceed 20% of the company's net assets at the end of the previous year [7][26]. - The net proceeds from the fundraising will be invested in projects related to vaccine research and production, with the company allowed to adjust the investment sequence and amounts based on actual needs [6][34]. - The board also approved a feasibility analysis report regarding the use of funds raised through the issuance of shares, confirming that the funds will be used for projects in the field of technological innovation [12][18]. Group 3 - The company has committed to measures to mitigate the dilution of immediate returns resulting from the share issuance, including maintaining stable business growth and accelerating project investment [40][46]. - The company has a strong talent reserve, with a stable management team and ongoing recruitment efforts to enhance its human resources [36]. - The company has established a comprehensive technical reserve, focusing on vaccine research and development, and has formed partnerships with academic institutions to enhance its innovation capabilities [37][38]. Group 4 - The company plans to strengthen its fundraising management to ensure compliance and effective use of the raised funds, with regular checks and disclosures on fund usage [42]. - The company aims to accelerate the construction of fundraising investment projects to enhance its competitiveness and sustainable development [43]. - The company has developed a profit distribution policy to ensure stable returns for investors, particularly small and medium shareholders [44][45].

证券代码：688319 证券简称：欧林生物 公告编号：2025-035 成都欧林生物科技股份有限公司 第七届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都欧林生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 18 日以现场及通讯方式在公司会议室召开第七届董事会第二次会议（以下简称"本 次会议"）。经全体董事同意，本次会议豁免通知时限要求。本次会议由公司董 事长樊绍文先生召集并主持，应出席董事 9 人，实际出席会议董事 9 人。本次会 议的通知、召开及审议程序符合《中华人民共和国公司法》《上海证券交易所科 创板股票上市规则》等法律法规、规范性文件及《成都欧林生物科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事审议，本次会议通过如下议案： （一）审议通过了《关于调减公司以简易程序向特定对象发行股票募集资 金总额暨调整发行方案的议案》 根据《中华人民共和国证券法》《上市公司证券发行注册管理 ...

成都欧林生物科技股份有限公司第七届董事会 独立董事专门会议 2025 年第一次会议决议 一、独立董事专门会议召开情况 成都欧林生物科技股份有限公司（以下简称"公司"）第七届董事会独立董 事专门会议 2025 年第一次会议于 2025 年 8 月 18 日在公司会议室以现场及通讯 方式召开。本次会议由独立董事陈正旭先生主持，应出席独立董事 3 名，实际出 席独立董事 3 名。本次会议的召集和召开程序符合《上市公司独立董事管理办法》 《上海证券交易所科创板股票上市规则》的相关规定，会议决议合法有效。 二、独立董事专门会议审议情况 本着勤勉尽责、客观公正的原则，经与会独立董事审议，以投票表决方式通 过以下议案： （一）审议通过了《关于调减公司以简易程序向特定对象发行股票募集资 金总额暨调整发行方案的议案》 经审阅，我们认为：公司编制的《成都欧林生物科技股份有限公司以简易程 序向特定对象发行人民币普通股（A 股）股票募集资金使用可行性分析报告（二 次修订稿）》符合《中华人民共和国公司法》《中华人民共和国证券法》及《上 市公司证券发行注册管理办法》等法律法规、规范性文件的有关规定，符合本次 发行的竞价结果及公司具体情况 ...

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. plans to issue A-shares to specific investors, which may dilute immediate returns, and has proposed measures to compensate for this dilution [1][5]. Financial Impact of the Issuance - The issuance is expected to impact key financial metrics, with three scenarios analyzed for the net profit attributable to shareholders in 2025 compared to 2024: a 10% increase, no change, and a 10% decrease [2][3][4]. - In the first scenario, the net profit would rise to CNY 22.83 million, with basic and diluted earnings per share (EPS) at CNY 0.0559 [3]. - In the second scenario, the net profit remains at CNY 20.76 million, with basic and diluted EPS at CNY 0.0508 [4]. - In the third scenario, the net profit would drop to CNY 18.68 million, with basic and diluted EPS at CNY 0.0458 [4]. Necessity and Reasonableness of the Issuance - The funds raised will be used for a vaccine R&D production base technology renovation project, which aligns with the company's core business and development strategy [5][6]. - The project aims to enhance production capabilities and ensure stable revenue generation, supporting long-term R&D and market promotion [5][6]. Company’s Preparedness in Talent, Technology, and Market - The company has a stable management team with extensive experience in the biopharmaceutical industry, ensuring ongoing support for sustainable development [6][7]. - The R&D team has over ten years of experience in vaccine development, focusing on both traditional and innovative vaccine projects [7][8]. - The company has established multiple vaccine R&D platforms and holds several patents, enhancing its competitive edge in the market [8]. Measures to Mitigate Dilution of Immediate Returns - The company commits to maintaining stable and rapid growth in its core business and accelerating the investment progress of the fundraising projects to enhance profitability [9][12]. - It will manage the raised funds strictly according to legal regulations to ensure compliance and effective use [11][12]. - The company plans to improve its profit distribution policy to ensure reasonable returns for investors, particularly small shareholders [12][13]. Commitments from Major Stakeholders - The controlling shareholder and actual controller have made commitments to uphold the company's independence and ensure the fulfillment of compensation measures for diluted returns [14][15]. - The board of directors and senior management have also pledged to avoid actions that could harm the company's interests and to adhere to the commitments made regarding return compensation [15][17].

成都欧林生物科技股份有限公司 关于以简易程序向特定对象发行人民币普通股（A 股） 股票募集资金使用可行性分析报告（二次修订稿） 一、本次募集资金使用计划 根据本次发行的竞价结果，发行对象拟认购金额合计为12,529.29万元，本 次发行募集资金总额不超过人民币3亿元且不超过最近一年末净资产的20%。在 扣除相关发行费用后的募集资金净额拟投资于以下项目： | 单位：万元 | | | | --- | --- | --- | | 序号 项目投资总额 | 项目名称 | 拟使用募集资金金额 | | 合计 29,000.00 | | 12,529.29 | | 上述项目符合国家产业政策和有关环境保护、土地管理等法律、行政法规 | | | | 规定，且均不涉及产能过剩行业，限制类、淘汰类行业，高耗能高排放行业。 | | | 在上述募集资金投资项目的范围内，公司可根据项目的进度、资金需求等 实际情况，对募集资金投资项目的投入顺序和具体金额进行适当调整。在本次 发行股票募集资金到位前，公司将根据募集资金投资项目的实际情况，以自筹 资金先行投入，并在募集资金到位后予以置换，不足部分由公司以自筹资金解 决。 （一）项目基本情况 本 ...